本帖最后由 老马 于 2012-1-13 21:20 编辑 2 @. h; c8 H, a) e
$ f' `2 G" ^: C$ I爱必妥和阿瓦斯丁的比较! l N. Z$ Z* W+ U* m# s, U
4 y: z" Z0 g# `/ |+ v) ]
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/3 k- U. T5 \7 D! O% P! h' y+ W3 X
* v S# ~* r' r$ M
8 Z0 G# g! C; A
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
) B* I3 O' G. u) ^0 g================================================== a% ]: \, p/ W
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: G* @5 I4 o- m+ E" N1 L- T; oPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
* D) }& \$ i* E) J& jResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* _: ~# m9 n9 S, x2 `
|